Spotlight Growth
No Result
View All Result
Monday, July 4, 2022
  • Login
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

Entasis Therapeutics (NASDAQ: ETTX) to be Acquired by Innoviva (NASDAQ: INVA) for $113 Million

by admin
May 23, 2022
in Bio/Med/Pharma
0
Entasis Therapeutics NASDAQ ETTX Innoviva NASDAQ INVA Merger Spotlight Growth

Entasis Therapeutics NASDAQ ETTX Innoviva NASDAQ INVA Merger Spotlight Growth

Entasis Therapeutics Holdings, Inc. (NASDAQ: ETTX) is engaged as a late-stage clinical biopharmaceutical company, which is focused on the research, development, and commercialization of advanced antibacterial therapies to treat multidrug-resistant pathogens. Shares of the biopharma company are rallying 21% through early trading on Monday, May 23, 2022. Over the past three months, Entasis Therapeutics has seen average daily volume of 69,060 shares. However, volume of 3.45 million shares or dollar volume of around $7.49 million, has already exchanged hands through early trading.

Shares of Entasis Therapeutics are gaining after the company announced that it has entered into a definitive agreement to be acquired by Innoviva, Inc. (NASDAQ: INVA), a holding company with an expansive portfolio of royalties and healthcare assets. Under the terms of the agreement, Innoviva will acquire all outstanding shares of Entasis at a price per share of $2.20 cash. The acquisition gives Entasis an equity valuation of $113 million.

Entasis Therapeutics was originally established back in 2015 as a spin-off from AstraZeneca. Since then, the company has developed an impressive clinical and pre-clinical pipeline of treatments for multidrug-resistant Gram-negative bacteria. The company’s leading product, SUL-DUR, achieved all its primary and secondary endpoints during a Phase 3 registrational trial and a New Drug Application is expected to be sent to the U.S. Food and Drug Administration during the third quarter 2022.

“This acquisition will build upon our overall strategy to acquire differentiated, high-potential assets in attractive, yet often overlooked, disease areas where our capital and capabilities can make a difference,” said Pavel Raifeld, Chief Executive Officer of Innoviva. “This transaction represents the next phase in our efforts to diversify our operations beyond our valuable royalty portfolio and will create significant value for patients, health systems and shareholders. We look forward to working with the Entasis team to advance sulbactam-durlobactam (SUL-DUR) and its broader novel antibacterial pipeline to address the urgent and serious threat posed by multidrug-resistant pathogens. Carbapenem-resistant Acinetobacter infections are an area of significant unmet medical need and, if approved by regulators, SUL-DUR could become the leading treatment for this disease.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

Tags: acquisitionbiopharma stocksbiopharmaceuticalsbiotechbiotech stocksclinical trialscommon stockemerging growthEntasis TherapeuticsETTXFDAFDA newsInnovivaINVAinvestinginvestmentmedicalMergermicrocap stocksmultidrug resistant bacteriaNASDAQnewspharmaceuticalspublic companysalessmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstocksstocks to watchtechtradingtreatment
Plugin Install : Widget Tab Post needs JNews - View Counter to be installed
  • Trending
  • Comments
  • Latest
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

November 22, 2021
Alfi NASDAQ ALF Ridesharing Tablet Rollout Spotlight Growth

Alfi, Inc. (NASDAQ: ALF) Climbs 51% After Entering Into Agreement with Miami-Based Fulfillment & Distribution Center For its Ridesharing Digital Tablet Rollout

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
Emergent Health OTC EMGE LOI Fusion Specialty Pharmacy Spotlight Growth

Emergent Health Corp. (OTC Pink: EMGE) Announces LOI to Acquire Fusion Specialty Pharmacy

June 29, 2022
Decibel Therapeutics NASDAQ DBTX Interim Data Phase 1b DB 020 Spotlight Growth

Decibel Therapeutics (NASDAQ: DBTX) Shares Positive Interim Data of its Ongoing Phase 1b Trial of DB-020

June 28, 2022
Ayurcann CSE AYUR OTCQB AYURF July Product Rollout Canada Spotlight Growth

Ayurcann (CSE: AYUR) (OTCQB: AYURF) Prepares for July New Product Rollout as Distribution Expansion Continues Across Canada

June 27, 2022
NeuroSense Therapeutics NASDAQ NRSN Stage III ALS Biomarker Study Spotlight Growth

NeuroSense Therapeutics (NASDAQ: NRSN) Details PrimeC’s Positive Results from Stage III ALS Biomarker Study

June 27, 2022

Recent News

Emergent Health OTC EMGE LOI Fusion Specialty Pharmacy Spotlight Growth

Emergent Health Corp. (OTC Pink: EMGE) Announces LOI to Acquire Fusion Specialty Pharmacy

June 29, 2022
Decibel Therapeutics NASDAQ DBTX Interim Data Phase 1b DB 020 Spotlight Growth

Decibel Therapeutics (NASDAQ: DBTX) Shares Positive Interim Data of its Ongoing Phase 1b Trial of DB-020

June 28, 2022

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us
Spotlight Growth

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested